Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital ...

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...

Bio-Rad’s business segments and geographic revenue distribution for Q4 2025 reveal the company’s diversified market presence: Segment Performance Analysis The Clinical Diagnostics segment emerged as ...

Bio-Rad Laboratories Inc. reports fourth-quarter results Thursday after market close, with investors looking to see whether the life sciences tools maker can sustain momentum from a strong prior ...

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading "Use of Non-GAAP Reporting." A reconciliation ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...